URGENT VENU Update + 52-Week High Movers

June 23, 2025

DENVER, Colo., Jun 23, 2025 (247marketnews.com)- Venu (NYSE:VENU) surged around 50%, since our initial alert a few weeks ago, and hit a new 52-week high on Friday. Despite its strong rally, VENU is trading lower today, offering a potential entry point as it still remains below most analysts’ price targets and its technical indicators remain bullish, with the 20-day SMA above the 50-day SMA, and the 50-day SMA above the 200-day SMA, signaling strong momentum.

J.W. Roth, Venu’s CEO, confirmed during the Q4 2024 earnings call that VENU to deliver its first development profit this year and this gain will materialize through strategic transactions like a sale-leaseback and, next year, VENU will achieve its first sizable operational profit, as new venues and hospitality assets (including multiple amphitheaters and entertainment centers) come online and begin generating consistent revenue. Venu’s innovative model and tight float make it a compelling opportunity for investors.

Today’s early dip seems largely driven by short selling, but the short side appears to be stepping into dangerous territory, as the current setup suggests a possible short squeeze scenario brewing.

Even more intriguing: VENU was expected to be added to the Russell 3000 in 2025, but the move was postponed due to an unusually tight float.

Please click here to view the full 24/7 Market News VENU Profile.

Many of the following listings are running thanks to the short squeeze fuel.

CorMedix (NASDAQ:CRMD) announced an expanded rollout of DefenCath with its Large Dialysis Organization (LDO) customer, targeting at least 50% more patients than initially planned starting in the second half of 2025. CEO Joseph Todisco said, “Their implementation of our product will provide access to DefenCath for thousands of adult patients at risk for catheter related bloodstream infections.” This development strengthens CorMedix’s position in combating life-threatening infections.

As a result, CorMedix raised its Q2 net sales guidance from $31 million to $35–$40 million, signaling stronger-than-anticipated revenue potential in the back half of the year.

Cidara Therapeutics (NASDAQ:CDTX) reported robust Phase 2b results for its long-acting antiviral CD388, achieving 76% efficacy at the 450 mg dose and no safety concerns across all doses. CEO Jeffrey Stein called the results “unprecedented in influenza,” while CMO Nicole Davarpanah noted, “The statistically significant and clinically meaningful results shown with CD388 mark a potential breakthrough for patients and the future of influenza prevention.” With an FDA meeting requested for Phase 3 planning, Cidara is poised for potential growth in the influenza prevention market.

Circle Internet (NYSE:CRCL) has seen an impressive post-IPO run and is taking the shorters, who are caught in this powerful short squeeze, to the woodshed

The crypto payments firm has benefited from the combination of high retail interest, tight float dynamics, and short interest positioning. As a result, CRCL has emerged as a momentum favorite in the fintech and Web3 space, and remains one of the most closely watched post-IPO names of the quarter.

DoorDash (NYSE:DASH) is on the move after a Raymond James upgrade to “Strong Buy” from “Outperform,” based on synergies with British delivery firm Deliveroo, which DoorDash is acquiring. The firm highlighted potential valuation upside from cross-market efficiencies.

Other 52-Week High Movers to Watch:

  • Cisco (NASDAQ:CSCO) has quietly notched a fresh 52-week high amid renewed enterprise spending on secure networking and AI infrastructure.
  • Exelixis (NASDAQ:EXEL)  hit new highs as investors rally behind its growing oncology pipeline and expanding commercial portfolio, including Cabometyx. The company has also attracted attention from strategic buyers, adding M&A speculation to the mix.
  • Kinross Gold (NYSE:KGC) is riding the wave of renewed gold interest, buoyed by macro uncertainty and central bank accumulation trends. A weaker dollar and rising inflation expectations have positioned gold miners like KGC for outperformance.
  • Kroger (NYSE:KR) reached fresh highs on resilience in consumer staples, strong loyalty metrics, and cost-control improvements. Analysts continue to favor KR for its combination of steady earnings and long-term margin expansion in a defensive sector.
  • Geospace Technologies (NASDAQ:GEOS) shares continue their steady ascent amid growing demand for seismic data acquisition and exploration services in both energy and defense. With oil prices firming and U.S. defense budgets expanding, GEOS’s niche offerings have found renewed relevance.Bottom of Form

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, CRMD, CDTX, CRCL, DASH, CSCO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.